CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), joins the Show to discuss recent Phase 3 trials and results of PRO140 monotherapy for the chronic suppression of HIV.

OTCQB: CYDY # PRO 140 # HIV/AIDS therapeutics # biotechnology company # Colon Cancer # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # humanized monoclonal antibodies